CONTACT US OR CALL 1.866.416.4636

Join Customer Site
Seeing More Matters
Call us at: 1.866.416.4636 | Europe: 00.800.0751.2020
  • Join
  • Customer Site

Shared Stories

We are delighted to share with you here the 'Share Your Story' segments that were recently featured in our monthly newsletter: Vevo News. Each month we ask scientists to summarize their research using the Vevo technology. Read about current research and its impact on human health using the Vevo Imaging Systems. To "Share Your Story", please email us.

From Vevo News - October, 2016

Image of the month:

Tumor showing targeted and non-targeted nanoparticles

Ultrasound and photoacoustic image of a tumor showing oxyhemoglobin (red), deoxyhemoglobin (blue), targeted nano particles (green) and non-targeted nano particles (yellow.)


From Vevo News - June, 2016

Share Your Success and Get Rewarded

Goody bag contains bluetooth speaker, mug, notepad and of course our mascot mouse.

Do you have an experience using our Vevo® technology that you'd like to share in our globally distributed newsletter? In this issue, we are asking you to tell us how our Ultra High Frequency Ultrasound or Photoacoustic System has advanced your research. If your story is shared, you will receive a FUJIFILM VisualSonics bag of branded goodies!.

Would you like to Share Your Story? Submit today!


Image of the month:

Rabbit embryo in a murine dam??!

A very amusing image of what looks like a rabbit embryo in a murine dam. Image courtesy of Dr. Gilles Renaud from Cochin Institute in Paris, France.


From Vevo News - May, 2016

Photoacoustic assessment of spatially and temporally varying oxygen saturation and perfusion in an orthotopic rat model of human hepatocellular carcinoma

Submitted by Dr. Richard Bouchard, Assistant Professor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Hypoxia, a deficiency in the amount of oxygen reaching tissue, plays a central role in poor HCC outcomes. Accumulating evidence shows that up to 50-60% of locally advanced solid tumors may exhibit heterogeneously distributed hypoxic (and anoxic) areas within the tumor mass. Because the supply and consumption of oxygen fluctuate temporally as well as spatially, these heterogeneous hypoxia regions also vary with time. It has been shown that the level of hypoxia has predictive correlation with HCC response to sorafenib, which is the only drug that is clinically approved for patients with advanced HCC. Development of a robust diagnostic platform capable of imaging these heterogeneous regions can be used to further our understanding and quantify these different hypoxia subtypes while evaluating spatial and temporal heterogeneity, and thus potentially creating novel therapeutic opportunities. Read full story.Read full story.



Would you like to Share Your Story? Submit today!

Image of the month:

Carotid Artery? Nope...look closer!

Although this may look like a carotid artery at first, what we are actually looking at is a longitudinal view of the radial artery bifurcation taken with our Vevo MD.


From Vevo News - April, 2016

Bench to Bedside



The fundamental goal of basic science (pre-clinical) research is to translate what we learn in cells and animal models to human physiology and human disease states.Today, it's not uncommon to hear terms such as “Knowledge Translation” and “Translational Research”. Recently, Petri et al. published a nice paper that showed this progression with clinical results using our Vevo Imaging System. They sought to determine if photoacoustics (PA) can be used on patients to measure oxygen saturation in chronic ulcers before and after treatment with a hemoglobin spray.. CLICK FOR DETAILS



Would you like to Share Your Story? Submit today!

Image of the month:

Here are a couple of awesome new applications for our brand new 4D Imaging Mode. Check out these videos showing incredible detail of the left atrium and right atrium! Learn more about 4D Mode Imaging


From Vevo News - February, 2016

Using the VevoLAZR to Characterize the Tumor Microenvironment and Develop Innovative Contrast Agents

Submitted by Dr. Giuseppe Ferrauto

Molecular Imaging is emerging as an innovative and multidisciplinary field of research aimed at visualizing and quantifying the signature of diseases, making it possible for an earlier and more precise diagnosis. The simultaneous application of different imaging modalities, each of them endowed with a different portfolio of applications and advantages, can enhance the information about the diseases being investigated. In this context, photoacoustic imaging (PAI) is attractive because it merges the advantages of ultrasound with the intrinsic optical absorption properties of molecules naturally occurring in tissues or exogenously administered. CLICK FOR DETAILS.


Giuseppe Ferrauto is a post-doctoral researcher at the Molecular Imaging Center- University of Torino (It) in Prof. Silvio Aime’s group. His research is mainly focuses on the development of innovative nano/micro-sized contrast agents and procedures (for MRI and PAI) for the molecular characterization of the tumor microenvironment. He received the EMIM (European Society for Molecular Imaging ) Best PhD Thesis Award in 2014 and the Vevo Travel Awards for Cancer Track in 2015 .


Would you like to Share Your Story? Submit today!

Image of the month:

Esophagus - Imaged using the Vevo MD

Vevo MD Ultra High-Frequency ultrasound is able to bring out details in scars that are not visible using conventional ultrasound. Here is an image of a scar formed after open heart surgery. Although barely visible using conventional ultrasound, the borders of the scar are very clear using Ultra High Frequency.


From Vevo News - January, 2016

Evaluating a Mouse Model of Intracerebral Hemorrhage Using Ultrasound and Photoacoustics

Submitted by Maria Stansczak, MS

Intracerebral hemorrhages (ICH) is a cause of stroke for which no effective drug therapy exists. Our work investigates a novel mouse model of ICH with high frequency ultrasound (US) and photoacoustics for long-term screening of potential preclinical therapeutics. Click here to read more.


Maria Stanczak is an ultrasound researcher and faculty member at Thomas Jefferson University in Philadelphia, PA. Her research interests include ultrasound contrast agents, subharmonic imaging, high frequency and photoacoustic scanning. Her recent award-winning research presented at RSNA 2015 focused on creation and monitoring of a novel mouse model for intracerebral hemmorhage using Vevo ultrasound and photoacoustics.


Would you like to Share Your Story? Submit today!

Image of the month:

Esophagus - Imaged using the Vevo MD

The layers of the esophageal wall can easily be distinguished using Vevo MD Ultra High-Frequency ultrasound. Physiology of the esophagus can also be observed while a volunteer swallows water. Click image to see video.
*The Vevo MD is not approved by Health Canada and the FDA. It is not authorized or available for sale in the United States and Canada.

From Vevo News - October, 2015From Vevo News - November, 2015

UHF Ultrasound Imaging for Preventative Medicine

Submitted by Dr. Frida Dangardt, Physician and Medical Researcher, University of Gothenburg, Sweden.

With improving treatment, the survival rate of children with different types of chronic disease has increased substantially in the last decade. Therefore, there is now an emerging problem of cardiovascular disease (CVD) affecting those who reach adulthood, as many of these diseases are known to have an adverse impact on the cardiovascular system. This holds true especially for children with type 1 diabetes (T1D) and chronic kidney disease (CKD), where cardiovascular changes are severe and CVD represents a large part of the increased mortality seen in these groups. In children with cystic fibrosis (CF), which could be considered an inflammatory disease, very little is known about the development of CVD, however, some studies in adults suggest that there are vascular changes involved. A program allowing a thorough characterisation of the different parts of the cardiovascular system (including vascular morphology and function, autonomic regulation and cardiorespiratory fitness) may facilitate prevention strategies and treatment optimisation to proactively minimise the cardiovascular consequences already in childhood.


New, ultra high frequency (UHF) ultrasound techniques are now available to enable visualisation of the separate layers of the vessel wall (intima, media and adventitia). This allows us to establish in which part of the vessel wall the initial changes appear, as well as possibly identifying changes at an earlier stage than with the composite measurement of IMT by conventional methods. We are then able to differ between the atherosclerotic changes in the intima driven by inflammation and lipids and the pressure driven changes in the smooth muscle of the media, or medial calcification as seen in patients with kidney disease (1). Using UHF B-mode ultrasound with technology from FUJIFILM VisualSonics, Inc. (under special ethics approval) with discrimination power of 30 μm, the feasibility of measuring intimal thickness (IT) of the radial and dorsal pedal arteries separately from medial thickness (MT) even in children has been demonstrated (2-4), and gender differences exist already early on (4). Increased IT has also been demonstrated in children with obesity (2). This may prove useful for treatment monitoring and for following disease progression.


1. Shroff R, Long D and Shanahan C. Mechanistic Insights into Vascular Calcification in CKD. JASN 2013; 24: 179-189.

2. Dangardt F, Osika W, Volkmann R, Gan LM, Friberg P. Obese children show increased intimal wall thickness and decreased pulse wave velocity. Clin Physiol Funct Imaging. 2008;28(5):287–93.

3. Osika W, Dangardt F, Gronros J, Lundstam U, Myredal A, Johansson M, et al. Increasing Peripheral Artery Intima Thickness From Childhood to Seniority. Arterioscler Thromb Vasc Biol. 2007;27(3):671–6.

4. Osika W, Dangardt F, Montgomery SM, Volkmann R, Gan LM, Friberg P. Sex differences in peripheral artery intima, media and intima media thickness in children and adolescents. Atherosclerosis. 2009;203(1):172–7.


Dr. Dangardt is a physician and medical researcher at the University of Gothenburg, Sweden. Her research has primarily focused on cardiovascular and metabolic conditions in children. Above, she discusses her current work on the cardiovascular effects of chronic childhood disease. This type of preventative research has the potential to help alleviate the burden caused by cardiovascular and metabolic disorders. It is also a great example of the utility of our Vevo imaging technology in the field of preventative medicine.


Would you like to Share Your Story? Submit today!

Image of the month:

What does UHF ultrasound imaging look like?

Watch a superficial vein with a valve. In this case when the subject holds their breath, you can see the blood flow actually stop and the valve close.

See the superficial vein in the arm at a point of bifurcation. In this case the speed of the blood flow varies as the subject varies clenches their fist, thus constricting and altering the blood flow.

Characterizing the Mouse Cardiovascular System in vivo using Vevo Imaging Systems

Submitted by Dr. Yu-Qing Zhou, PhD from the Hospital for Sick Children, Toronto, Canada.

At the Mouse Imaging Centre of the Hospital for Sick Children in Toronto, we have collaborated with VisualSonics Inc. since early 2000 and used their products from the very first generation to the most advanced versions. With the state-of-the-art technologies from VisualSonics, we have conducted very extensive research on cardiovascular physiology and in vivo phenotyping of genetic mouse models of human diseases. We have established comprehensive methodologies for mouse cardiovascular imaging using high frequency ultrasound (Physiological Genomics 18:232-244;2004), and successfully applied the established methodology to the phenotyping of mutant mouse models with human diseases. These methods have been widely accepted in this field. In recent years we have used the Vevo2100 imaging system together with other micro-imaging technologies to evaluate the association between aortic flow dynamics and atherogenesis in mouse models and also to study the mouse fetal and placental physiology (Physiological Genomics 46:602-614;2014). Vevo systems have played a central role in more than 30 publications from our group and continue to be one of our most heavily used imaging technologies.


Would you like to Share Your Story? Submit today!

Image of the month:

The left ventricle in 4D using the Vevo 3100!

Coming soon, our new 4D mode on the Vevo 3100 Imaging System will allow you to look at your 3D images over time. Click on the thumbnails below to view a 4D image that was taken from a parasternal short axis view of the mouse heart. Multiple 3D volumes were then drawn across the entire cardiac cycle. The result is an incredible reconstruction of the heart from diastole to systole.

From Vevo News - September, 2015

Multimodal Imaging And The Newest Cancer Theranostic Agent

Shared by Dr. Peng Huang (the latest winner in our 2015 Vevo Young Investigator awards competition presented at WMIC 2015, Honolulu, Hawaii. See photo below).

From Left to Right: Andrew Heinmiller, Dr. Peng Huang, Daniel Meng, Andrew Needles

Dr. Peng Huang presented his work on the development of a clinically translatable cancer theranostic agent at the World Molecular Imaging Conference in Hawaii. This therapy uses a near-infrared (NIR) cyanine dye and human serum albumin (HSA) conjugate for NIRfluorescence/photoacoustic/thermal multimodality imaging and photothermal tumor ablation. This work was supported by the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH).Click here to read Dr. Peng Huang's complete bio.


Click here to learn more about theranostic agent development, published in ACS Nano.

Would you like to Share Your Story? Submit today!

Image of the month:

Multimodal Imaging Of Bacterial Infection

Bacterial infection is a major cause of morbidity and mortality, especially in the case of antibiotic-resistant strains of S. aureus.   A small animal model that uses noninvasive imaging provides a valuable system to study pathogenesis, its treatments and diagnostic approaches. Click here to see enlarged image with full story.

From Vevo News - August, 2015

In Vivo Imaging Of Kidney Pathologies

Dr. Carlton Bates heads an NIH funded research program at the University of Pittsburgh which also benefits from his clinical service as the Chief of Pediatric Nephrology. Many of the mouse models Dr. Bates has generated mimic congenital structural kidney diseases, which are the leading causes of kidney disease in children.

In fact, Vesicoureteral reflux, which is backflow of urine from the bladder into the kidneys affects 1-2% of the population and the state-of-the-art for detecting reflux was in euthanized animals; this loses the normal physiology of live animals and prevents repeated testing of animals. In addition, abnormal bladder function is associated with a myriad of clinical complications (including hydronephrosis) for which there are currently limited therapies.


With high frequency ultrasound guided research, his laboratory has accomplished the following:

1. Generated an in vivo assay using microbubble contrast ultrasound imaging to detect vesicoureteral reflux (VUR) in live mice.

2. Generated 3D reconstructions of the ureter and renal pelvis with the contrast to measure the degree of reflux.

3. Quantified progressive increases in bladder volumes and worsening hydronephrosis (dilatation of the renal pelvis) in aged mutant mice.

Would you like to Share Your Story? Submit today!

Image of the month:

Ultrasound Of The Bladder

The ultrasound of the bladder is a representative trans abdominal view and clearly shows an infiltrating mass, albeit a small one, into the lumen of the bladder.
Click here or the thumbnail to watch the cine loop of micro-vessels surrounding the bladder.

From Vevo News - July, 2015

The Challenges Of in vivo Fibrosis Imaging

Submitted by Terri A. Swanson, Senior Scientist, Comparative Medicine, Pfizer Inc. and

Theresa Tuthill, Head of Cardiovascular, Metabolic, and Musculoskeletal Imaging for the Clinical and Translational Imaging group at Pfizer Inc.

Terri Swanson, Theresa Tuthill and their team at Pfizer share their story and navigate through some of the translational challenges in developing imaging methods for fibrosis. While fibrosis (tissue scarring) is a normal response to injury, the deposition of connective tissue to form scars challenges the organ to function normally. The mechanism of fibrosis is still unclear, and its onset/progression is generally visualized via biopsy and histology. Drug development for fibrotic diseases brings a more demanding challenge – characterizing and monitoring the onset and progression of fibrosis for in vivo longitudinal studies to assist in Pfizer’s efforts to develop novel treatments for these diseases.

This challenge demanded the knowledge to generate the right in vivo model for longitudinal monitoring by high frequency ultrasound waves. Pfizer teams led by Terri Swanson and Theresa Tuthill explored a variety of techniques and quantitative analyses to address this complex challenge. In a recent webinar, they share how they brought their individual expertise in high frequency ultrasound to address the science of developing therapeutics for fibrosis in the liver and heart.
Click here to watch the webinar.

Would you like to Share Your Story? Submit today!

Image of the month:

Screening Fibrosis in vivo

Liver ultrasound shown in its transverse view in normal (#14) and treated (#57) rats. Background image is a trichrome stained rat liver histology.
Click here to see the larger image.

From Vevo News - June, 2015

Multimodality Contrast Agents For Molecular Imaging

Submitted by Elizabeth Huynh, Dr. Zheng Lab, University of Toronto

Converting nanoparticles or monomeric compounds into larger supramolecular structures by endogenous or external stimuli is increasingly popular because these materials are useful for imaging and treating diseases. However, conversion of microstructures to nanostructures is less common.

Here, Elizabeth shows the conversion of porphyrin microbubbles to nanoparticles using low-frequency ultrasound and their potential application in tumor imaging and therapy. The initial idea for a porphyrin microbubble was conceived through an international collaboration requiring a trimodal contrast agent for ultrasound, photoacoustic and fluorescence imaging. The contrast agent needed to have a micrometre-size gas core for ultrasound imaging and additional optical properties for photoacoustic and fluorescence imaging. The porphyrin–phospholipid building block developed in the Zheng lab met all the requirements for this type of multimodal contrast agent and it was used to synthesize porphyrin-based microbubbles.

Elizabeth goes on to explain the genesis of this idea in her article in the March issue of Nature Nanotechnology. Click here to read about Elizabeth's Journey here.

Would you like to Share Your Story? Submit today!

Image of the month:

Tracking Stem Cells in vivo

Click on the image to see larger image and full description.

From Vevo News - May, 2015

A New Approach To Restoring Cardiac Health

Currently, the only major treatment for heart failure is transplantation. However, it is estimated that less than 30% of patients survive long enough to receive their new hearts. The local cell death following myocardial infarction plays a major role in the progression of cardiac dysfunction.

Dr.Mike Davis' research team at Emory University School of Medicine focuses on various aspects of cardiac regeneration and preservation. His team (part of the joint Biomedical Engineering program at Emory and Georgia Institute of Technology) uses molecular based and biomaterials-based approaches to restore function after cardiac injury.

To learn more about research by Dr. Mike Davis, click here.

Above: A photoacoustic image of labeled cells in the rat myocardium. Click here to view larger, animated version with full description.

Would you like to Share Your Story? Submit today!

Click on the image to see larger image and full description.

From Vevo News - April, 2015

Advanced Theranostic Imaging For Drug Discovery

Submitted by: Dr. Fabian Kiessling with his team at the Institute ofor Experimental Molecular Imaging (ExMI*), University Hospital Aachen and Helmholtz Institute for Biomedical Engineering at RWTH Aachen University.

The merging of drug therapy and diagnostics to advance personalized medicine is one definition of theranostics. Research in advanced theranostics elevates this concept by merging nanotechnology to benefit drug discovery.

Such research is the direction for Dr. Fabian Kiessling and his team at the Institute for Experimental Molecular Imaging ( ExMI*), University Hospital Aachen and Helmholtz Institute for Biomedical Engineering at RWTH Aachen University.

In fact, a recent report by Lammers et al addresses one of the major challenges of biomedical and (nano-) pharmaceutical research. Lammers published on the efficient and safe opening of the blood brain barrier using USPIO-loaded polymeric microbubbles in combination with high frequency ultrasound imaging on the Vevo 2100 and showed the delivery of a fluorescent macromolecular model drug into the brain tissue.

Click here to see image.

*ExMI is part of a consortium that is recommended as a Euro-BioImaging node for preclinical multimodal molecular imaging.

Click on the image to see larger image and full description.

From Vevo News - March, 2015

Predicting Tumor Recurrence Using Vevo LAZR

Submitted by Srivalleesha Mallidi, Ph.D., Research Fellow, Harvard Medical School, Wellman Center for Photomedicine, Boston, MA, USA

The unique feature of obtaining tumor structure and functional properties using the Vevo LAZR system enabled us to monitor therapies such as photodynamic therapy and predict tumor recurrence. By precisely monitoring the change in oxygen saturation within the 3D tumor volume, we could predict regions that did not have sufficient therapeutic effect and hence recurred at later time point. Information on the likelihood of tumor regrowth that normally would have been available only upon actual regrowth (10-30 days post treatment) in xenograft tumor model, was available within 24-hrs of treatment using PAI, thus making early intervention a possibility. We hope to extend this technique to guide and monitor various cancer targeted therapies. This work is recently published in Theranostics and was chosen for the cover feature.

Reference: Prediction of tumor recurrence and therapy monitoring using ultrasound-guided photoacoustic imaging. Mallidi et al, 2015; Theranostics

Click on the image to see larger image and full description.

From Vevo News - February, 2015

New CV Protocol Using Vevo 2100

Submitted by Craig Goergen, Frederick W. Damen and Arvin H. Soepriatna of Purdue University

Through our collaboration with VisualSonics, we have developed a new protocol for collecting in vivo ECG and respiratory-gated 3D ultrasound volumes in mice in order to visualize complex cardiac motion. Current efforts are focused on using these datasets for subsequent computational flow dynamics and biomechanical modeling. We hope future studies can use this technique to study disease models of myocardial infarction, aortic stenosis, or ventricular hypertrophy.

Reference: Damen FW, Goergen CJ. 4 -Dimensional ultrasound imaging of left -ventricular dynamics. Oral Presentation – 14th Biennial Meeting, International Society of Applied Cardiovascular Biology. Cleveland, Ohio, April 3rd, 2014.

Image of the month:

Imaging for Bacterial Infection

Click on the image to see larger image and full description.